Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6685097 | 0.87 | RIPK1 (0.56) | RIPK1IDO1ESR1SLC6A2TAAR1 | |
| SCHEMBL9718549 | 0.80 | RIPK1 (0.50) | RIPK1ESR1SLC6A2TAAR1NPC1 | |
| SCHEMBL125429 | 0.79 | IDO1 (0.63) | IDO1TAAR1CYP2D6 | |
| SCHEMBL29365799 | 0.79 | IDO1 (0.63) | IDO1TAAR1CYP2D6 | |
| SCHEMBL6685032 | 0.78 | RIPK1 (0.48) | RIPK1ESR1SLC6A2TAAR1CYP2D6 | |
| SCHEMBL10318075 | 0.76 | RIPK1 (0.47) | RIPK1ESR1SLC6A2TAAR1NPC1 | |
| SCHEMBL21711085 | 0.76 | RIPK1 (0.47) | RIPK1ESR1SLC6A2TAAR1NPC1 | |
| SCHEMBL21785793 | 0.76 | RIPK1 (0.47) | RIPK1IDO1ESR1SLC6A2TAAR1 | |
| SCHEMBL396630 | 0.76 | RIPK1 (0.47) | RIPK1ESR1SLC6A2TAAR1 | |
| SCHEMBL358741 | 0.76 | RIPK1 (0.47) | RIPK1ESR1SLC6A2TAAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | RIPK1 629/4885IDO1 788/4885ESR1 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.